120 related articles for article (PubMed ID: 12540243)
21. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
Corbin JD
Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
[TBL] [Abstract][Full Text] [Related]
23. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury.
Ahn BO; Kang KK; Ahn GJ; Kwon JW; Kim WB; Kang KS; Lee YS
Int J Impot Res; 2003 Dec; 15(6):405-11. PubMed ID: 14671658
[TBL] [Abstract][Full Text] [Related]
25. New achievement and novel therapeutic applications of PDE5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(3 Suppl):45-50. PubMed ID: 16042360
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
27. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
Kang KK; Yu JY; Yoo M; Kwon JW
Int J Impot Res; 2005; 17(5):409-16. PubMed ID: 15920460
[TBL] [Abstract][Full Text] [Related]
28. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
29. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.
Sui Z; Guan J; Macielag MJ; Jiang W; Qiu Y; Kraft P; Bhattacharjee S; John TM; Craig E; Haynes-Johnson D; Clancy J
Bioorg Med Chem Lett; 2003 Feb; 13(4):761-5. PubMed ID: 12639576
[TBL] [Abstract][Full Text] [Related]
31. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
[TBL] [Abstract][Full Text] [Related]
32. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
33. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
34. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
35. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
36. Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
Bischoff E
Int J Impot Res; 2004 Jun; 16 Suppl 1():S11-4. PubMed ID: 15224129
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
de Tejada IS
Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
[TBL] [Abstract][Full Text] [Related]
38. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
Pickard R
Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
[No Abstract] [Full Text] [Related]
39. Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors.
Zheng H; Li L; Sun B; Gao Y; Song W; Zhao X; Gao Y; Xie Z; Zhang N; Ji J; Yuan H; Lou H
Eur J Med Chem; 2018 Apr; 150():30-38. PubMed ID: 29505934
[TBL] [Abstract][Full Text] [Related]
40. Commentary on apomorphine versus sildenafil for erectile dysfunction.
Carson CC
J Urol; 2008 May; 179(5 Suppl):S95-6. PubMed ID: 18405768
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
